Division of Allergy and Clinical Immunology, University of Colorado School of Medicine, 12700 East 19th Avenue 10C03, Aurora, CO 80045, USA.
Division of Allergy and Clinical Immunology, University of Colorado School of Medicine, 12700 East 19th Avenue 10C03, Aurora, CO 80045, USA.
Immunol Allergy Clin North Am. 2024 Aug;44(3):453-467. doi: 10.1016/j.iac.2024.03.004. Epub 2024 May 18.
This study focuses on quality of life (QoL) assessment in chronic urticaria, delving into tools, disease-specific measures, and its profound impact. With expanding therapeutic options, understanding QoL becomes crucial. QoL measures often involve comparisons of patient-reported outcomes in addition to quantitative measures of disease control. Emerging tools include the Urticaria Activity and Impact Measure, which may provide a balanced evaluation. In addition to discussions of the various QoL measures, the psychological impact of chronic urticaria are highlighted, covering emotional burden, stress, and psychiatric comorbidities. Finally, the economic impacts reveal escalating health care costs and cost-effectiveness considerations of therapies like omalizumab.
本研究关注慢性荨麻疹的生活质量（QoL）评估，深入探讨了工具、疾病特异性措施及其深远影响。随着治疗选择的不断扩大，了解 QoL 变得至关重要。QoL 测量通常涉及患者报告结果的比较，以及疾病控制的定量测量。新兴工具包括荨麻疹活动和影响测量，它可以提供平衡的评估。除了讨论各种 QoL 测量外，还强调了慢性荨麻疹的心理影响，包括情绪负担、压力和精神共病。最后，经济影响揭示了医疗保健成本的不断增加和奥马珠单抗等疗法的成本效益考虑。
